LivaNova Stock Price, News & Analysis (NASDAQ:LIVN)

$80.88 0.57 (0.71 %)
(As of 01/18/2018 02:31 PM ET)
Previous Close$80.31
Today's Range$79.82 - $81.10
52-Week Range$45.67 - $88.56
Volume208,700 shs
Average Volume313,464 shs
Market Capitalization$3.90 billion
P/E Ratio21.57
Dividend YieldN/A
BetaN/A

About LivaNova (NASDAQ:LIVN)

LivaNova logoLivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company's segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.

Receive LIVN News and Ratings via Email

Sign-up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:LIVN
CUSIPN/A
Phone+44-20-37865275

Debt

Debt-to-Equity Ratio0.04%
Current Ratio2.03%
Quick Ratio1.42%

Price-To-Earnings

Trailing P/E Ratio21.568
Forward P/E Ratio25.43
P/E Growth2.17

Sales & Book Value

Annual Sales$1.21 billion
Price / Sales3.21
Cash Flow$5.45 per share
Price / Cash14.83
Book Value$34.99 per share
Price / Book2.31

Profitability

Trailing EPS$3.75
Net Income$-62,780,000.00
Net Margins4.63%
Return on Equity9.33%
Return on Assets6.82%

Miscellaneous

Employees4,500
Outstanding Shares48,210,000

LivaNova (NASDAQ:LIVN) Frequently Asked Questions

What is LivaNova's stock symbol?

LivaNova trades on the NASDAQ under the ticker symbol "LIVN."

How were LivaNova's earnings last quarter?

LivaNova PLC (NASDAQ:LIVN) announced its quarterly earnings data on Thursday, November, 2nd. The company reported $0.93 earnings per share for the quarter, beating analysts' consensus estimates of $0.76 by $0.17. The firm had revenue of $309.70 million for the quarter, compared to analyst estimates of $301.22 million. LivaNova had a net margin of 4.63% and a return on equity of 9.33%. The business's quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.78 earnings per share. View LivaNova's Earnings History.

When will LivaNova make its next earnings announcement?

LivaNova is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for LivaNova.

What guidance has LivaNova issued on next quarter's earnings?

LivaNova updated its FY17 earnings guidance on Thursday, November, 2nd. The company provided earnings per share guidance of $3.30-3.45 for the period, compared to the Thomson Reuters consensus estimate of $3.24.

Where is LivaNova's stock going? Where will LivaNova's stock price be in 2018?

7 equities research analysts have issued 12 month price objectives for LivaNova's stock. Their forecasts range from $50.00 to $97.00. On average, they expect LivaNova's share price to reach $78.17 in the next twelve months. View Analyst Ratings for LivaNova.

What are Wall Street analysts saying about LivaNova stock?

Here are some recent quotes from research analysts about LivaNova stock:

  • 1. According to Zacks Investment Research, "LivaNova PLC is a medical technology company which focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company's operating units consists of Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation. LivaNova PLC, formerly known as Cyberonics, Inc., is based in London, United Kingdom. " (12/21/2017)
  • 2. Canaccord Genuity analysts commented, "We remain HOLD-rated on shares of LIVN in the wake of their announcement that the company would purchase the remaining part of ImThera – an early-stage company focused on neuromodulation to treat obstructive sleep apnea – that it does not already own. While the technology fits synergistically within LIVN’s strong neuromodulation franchise to some degree, the call point will be different than its current offering (ENTs vs. neurosurgeons). The firm thinks it can leverage its growing OUS neuromodulation sales presence to drive some near-term ImThera revenue (expectations not disclosed) in Europe; however, we expect contributions will be minimal for the next few years at least, primarily on the basis of current reimbursement coverage, or lack thereof, and need for long-term data to catalyze ENT surgeons to adopt the therapy, according to our due diligence." (12/5/2017)
  • 3. Needham & Company LLC analysts commented, "LIVN announced that it is exploring strategic options for its low growth and low margin CRM business. This shouldn’t come as a huge surprise since management had previously hinted a potential sale of the CRM business. We think a CRM sale would increase LIVN’s revenue growth; the EPS impact hinges on price, CRM margins, and use of proceeds. We think a sale would be neutral to slightly dilutive if the proceeds were used for share repurchases and/or debt repayment though we note that there would likely be near-term hit to EPS between when the sale is announced and when LIVN is able to deploy the proceeds to offset any dilution." (9/14/2017)
  • 4. BTIG Research analysts commented, "Last week, while we were at our Snowbird conference, LIVN reported Q4 results and released initial FY17 guidance. Once again, we are lowering our estimates for LIVN. While shares are inexpensive, we do not see how it will grow in the future unless major M&A or R&D efforts take place, moving LIVN into new markets. Given most of LIVN’s markets are flat to declining, we would be inclined to wait for the company to show intentions to enter new markets before recommending shares. We don’t expect an inflection point on cardiac surgery anytime soon and while new iterations in Neuromod may pad growth in 2H17, we think the lower end of the 1-3% revenue growth guidance would be a good achievement. There remain considerable areas of opportunity on the synergy side, which should support EPS growth. With the first innings of physical integration behind them, we think the co. is in a better position to focus on more sizeable areas of savings such as purchasing/direct procurement. However, we think the lack of revenue growth is more important than synergies and we reiterate our Neutral rating." (3/10/2017)

Who are some of LivaNova's key competitors?

Who owns LivaNova stock?

LivaNova's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.53%) and Waverton Investment Management Ltd (0.23%). Company insiders that own LivaNova stock include Alfred J Novak, Daniel Jeffrey Moore, Hugh M Morrison, Jacques Gutedel, Sharon O'kane and Two SCA Equinox. View Institutional Ownership Trends for LivaNova.

Who sold LivaNova stock? Who is selling LivaNova stock?

LivaNova's stock was sold by a variety of institutional investors in the last quarter, including Waverton Investment Management Ltd. Company insiders that have sold LivaNova company stock in the last year include Alfred J Novak, Daniel Jeffrey Moore and Hugh M Morrison. View Insider Buying and Selling for LivaNova.

Who bought LivaNova stock? Who is buying LivaNova stock?

LivaNova's stock was acquired by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc.. View Insider Buying and Selling for LivaNova.

How do I buy LivaNova stock?

Shares of LivaNova can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is LivaNova's stock price today?

One share of LivaNova stock can currently be purchased for approximately $80.88.

How big of a company is LivaNova?

LivaNova has a market capitalization of $3.90 billion and generates $1.21 billion in revenue each year. The company earns $-62,780,000.00 in net income (profit) each year or $3.75 on an earnings per share basis. LivaNova employs 4,500 workers across the globe.

How can I contact LivaNova?

LivaNova's mailing address is 20 Eastbourne Terrace, LONDON, W2 6LG, United Kingdom. The company can be reached via phone at +44-20-37865275 or via email at [email protected]


MarketBeat Community Rating for LivaNova (LIVN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  106 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  209
MarketBeat's community ratings are surveys of what our community members think about LivaNova and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

LivaNova (NASDAQ:LIVN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.432.432.432.25
Ratings Breakdown: 1 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $78.17$78.17$71.50$61.33
Price Target Upside: 6.54% downside6.54% downside4.70% upside24.62% upside

LivaNova (NASDAQ:LIVN) Consensus Price Target History

Price Target History for LivaNova (NASDAQ:LIVN)

LivaNova (NASDAQ:LIVN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/5/2017Canaccord GenuityReiterated RatingHold$76.00LowView Rating Details
12/5/2017Needham & Company LLCBoost Price TargetBuy -> Buy$93.00 -> $97.00LowView Rating Details
11/7/2017BTIG ResearchReiterated RatingHoldN/AView Rating Details
11/3/2017Piper Jaffray CompaniesReiterated RatingBuy$85.00N/AView Rating Details
11/3/2017Jefferies GroupBoost Price TargetBuy$80.00 -> $91.00N/AView Rating Details
8/15/2017WBB SecuritiesDowngradeHold -> Sell$50.00LowView Rating Details
8/11/2017Berenberg BankReiterated RatingBuy$70.00LowView Rating Details
2/29/2016Kepler Capital MarketsBoost Price TargetHold$63.00 -> $66.00N/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

LivaNova (NASDAQ:LIVN) Earnings History and Estimates Chart

Earnings by Quarter for LivaNova (NASDAQ:LIVN)

LivaNova (NASDAQ LIVN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018        
11/2/2017Q3 2017$0.76$0.93$301.22 million$309.70 millionViewN/AView Earnings Details
8/9/2017Q2 2017$0.82$1.01$315.75 million$321.40 millionViewListenView Earnings Details
5/3/20173/31/2017$0.68$0.71$285.10 millionViewListenView Earnings Details
3/1/2017Q416$0.79$0.82$301.45 million$310.60 millionViewListenView Earnings Details
11/2/2016Q316$0.76$0.78$299.40 million$295.30 millionViewN/AView Earnings Details
8/3/2016Q2 2016$0.68$0.87ViewN/AView Earnings Details
5/4/2016Q1 2016$0.67$0.54ViewN/AView Earnings Details
8/20/2015Q3 2015$0.63$0.72ViewN/AView Earnings Details
6/4/2015Q2 2015$0.63$0.64ViewN/AView Earnings Details
2/26/2015Q1 2015$0.57$0.59ViewN/AView Earnings Details
11/20/2014Q4 2014$0.59$0.63ViewN/AView Earnings Details
8/21/2014Q3 2014$0.56$0.53ViewN/AView Earnings Details
6/4/2014Q2 2014$0.55$0.55ViewN/AView Earnings Details
2/20/2014Q1 2014$0.49$0.51ViewN/AView Earnings Details
11/21/2013Q4 2013$0.49$0.50ViewN/AView Earnings Details
8/22/2013Q3 2013$0.46$0.48ViewN/AView Earnings Details
6/5/2013Q2 2013$0.43$0.46ViewN/AView Earnings Details
2/22/2013Q1 2013$0.38$0.47ViewN/AView Earnings Details
11/16/2012Q4 2012$0.39$0.44ViewN/AView Earnings Details
8/28/2012Q3 2012$0.36$0.38ViewN/AView Earnings Details
6/6/2012Q2 2012$0.35$0.38ViewN/AView Earnings Details
2/24/2012Q1 2012$0.30$0.42ViewN/AView Earnings Details
11/18/2011Q4 2011$0.30$0.32ViewN/AView Earnings Details
8/25/2011Q3 2011$0.26$0.28ViewN/AView Earnings Details
6/2/2011Q2 2011$0.29$0.26ViewN/AView Earnings Details
3/2/2011Q1 2011$0.24$0.25ViewN/AView Earnings Details
11/22/2010Q4 2010$0.25$0.25ViewN/AView Earnings Details
8/25/2010Q3 2010$0.21$0.25ViewN/AView Earnings Details
6/2/2010Q2 2010$0.33$0.40ViewN/AView Earnings Details
2/17/2010Q1 2010$0.25$0.26ViewN/AView Earnings Details
11/18/2009Q4 2009$0.20$0.32ViewN/AView Earnings Details
8/19/2009Q3 2009$0.18$0.23ViewN/AView Earnings Details
6/3/2009Q2 2009$0.19$0.22ViewN/AView Earnings Details
2/18/2009Q1 2009$0.10$0.15ViewN/AView Earnings Details
11/19/2008Q4 2008$0.06$0.14ViewN/AView Earnings Details
8/21/2008Q3 2008$0.03$0.08ViewN/AView Earnings Details
6/11/2008Q2 2008$0.01$0.04ViewN/AView Earnings Details
2/20/2008Q1 2008($0.09)($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

LivaNova (NASDAQ:LIVN) Earnings Estimates

2018 EPS Consensus Estimate: $3.70
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.81$0.81$0.81
Q2 20181$0.98$0.98$0.98
Q3 20181$0.91$0.91$0.91
Q4 20181$1.00$1.00$1.00
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for LivaNova (NASDAQ:LIVN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

LivaNova (NASDAQ LIVN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.28%
Institutional Ownership Percentage: 86.00%
Insider Trades by Quarter for LivaNova (NASDAQ:LIVN)
Institutional Ownership by Quarter for LivaNova (NASDAQ:LIVN)

LivaNova (NASDAQ LIVN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/16/2018Daniel Jeffrey MooreDirectorSell1,000$82.15$82,150.00View SEC Filing  
12/15/2017Daniel Jeffrey MooreDirectorSell1,000$80.80$80,800.00View SEC Filing  
11/29/2017Hugh M MorrisonDirectorSell1,830$88.00$161,040.00View SEC Filing  
11/22/2017Alfred J NovakDirectorSell2,000$85.77$171,540.00View SEC Filing  
11/15/2017Daniel Jeffrey MooreDirectorSell1,000$81.39$81,390.00View SEC Filing  
10/16/2017Daniel Jeffrey MooreDirectorSell1,000$74.58$74,580.00View SEC Filing  
9/15/2017Daniel Jeffrey MooreDirectorSell1,000$68.55$68,550.0057,296View SEC Filing  
8/15/2017Daniel Jeffrey MooreDirectorSell1,000$60.76$60,760.0058,296View SEC Filing  
7/17/2017Daniel Jeffrey MooreDirectorSell1,000$61.55$61,550.0056,437View SEC Filing  
6/15/2017Daniel Jeffrey MooreDirectorSell1,000$60.80$60,800.0057,437View SEC Filing  
5/23/2017Sharon O'kaneDirectorBuy1,000$58.58$58,580.001,000View SEC Filing  
5/22/2017Alfred J NovakDirectorSell1,000$58.49$58,490.0012,020View SEC Filing  
5/5/2017Hugh M MorrisonDirectorSell3,215$55.89$179,686.352,000View SEC Filing  
4/17/2017Daniel Jeffrey MooreDirectorSell1,000$51.32$51,320.0059,437View SEC Filing  
3/15/2017Daniel Jeffrey MooreDirectorSell1,000$50.21$50,210.0060,437View SEC Filing  
9/22/2016Two S.C.A. EquinoxMajor ShareholderSell185,000$61.54$11,384,900.00View SEC Filing  
9/21/2016Two S.C.A. EquinoxMajor ShareholderSell391,379$60.69$23,752,791.51View SEC Filing  
9/16/2016Two S.C.A. EquinoxMajor ShareholderSell75,213$59.86$4,502,250.18View SEC Filing  
9/13/2016Two S.C.A. EquinoxMajor ShareholderSell25,408$60.02$1,524,988.16View SEC Filing  
9/8/2016Two S.C.A. EquinoxMajor ShareholderSell208,000$60.52$12,588,160.00View SEC Filing  
8/9/2016Jacques GutedelInsiderSell4,000$60.52$242,080.0010,948View SEC Filing  
5/24/2016Daniel Jeffrey MooreDirectorSell1,000$50.07$50,070.0064,137View SEC Filing  
5/19/2016Hugh M MorrisonDirectorSell3,600$48.00$172,800.005,215View SEC Filing  
5/6/2016Alfred J NovakDirectorSell4,000$51.12$204,480.0013,020View SEC Filing  
4/15/2016Daniel Jeffrey MooreDirectorSell1,000$54.81$54,810.0064,437View SEC Filing  
3/15/2016Daniel Jeffrey MooreDirectorSell1,000$56.88$56,880.0065,437View SEC Filing  
2/16/2016Daniel Jeffrey MooreDirectorSell1,000$56.88$56,880.0066,437View SEC Filing  
1/15/2016Daniel Jeffrey MooreDirectorSell1,000$52.64$52,640.0067,437View SEC Filing  
12/15/2015Daniel Jeffrey MooreDirectorSell2,500$53.97$134,925.0068,437View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

LivaNova (NASDAQ LIVN) News Headlines

Source:
DateHeadline
Daniel Jeffrey Moore Sells 1,000 Shares of LivaNova PLC (LIVN) StockDaniel Jeffrey Moore Sells 1,000 Shares of LivaNova PLC (LIVN) Stock
www.americanbankingnews.com - January 17 at 9:32 PM
LivaNova PLC (LIVN) Given Average Rating of "Hold" by AnalystsLivaNova PLC (LIVN) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - December 26 at 7:53 AM
Globus Medical (GMED) versus LivaNova (LIVN) Financial ReviewGlobus Medical (GMED) versus LivaNova (LIVN) Financial Review
www.americanbankingnews.com - December 24 at 1:32 PM
LivaNova (LIVN) Stock Rating Lowered by Zacks Investment ResearchLivaNova (LIVN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - December 22 at 12:10 AM
LivaNova Plc breached its 50 day moving average in a Bearish Manner : LIVN-US : December 21, 2017LivaNova Plc breached its 50 day moving average in a Bearish Manner : LIVN-US : December 21, 2017
finance.yahoo.com - December 21 at 9:27 AM
LivaNova (LIVN) Downgraded to "Hold" at ValuEngineLivaNova (LIVN) Downgraded to "Hold" at ValuEngine
www.americanbankingnews.com - December 20 at 10:10 PM
Head to Head Contrast: Intersect ENT (XENT) & LivaNova (LIVN)Head to Head Contrast: Intersect ENT (XENT) & LivaNova (LIVN)
www.americanbankingnews.com - December 20 at 7:14 AM
LivaNova (LIVN) Lowered to "Buy" at BidaskClubLivaNova (LIVN) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - December 17 at 5:20 PM
Analyzing Globus Medical (GMED) and LivaNova (LIVN)Analyzing Globus Medical (GMED) and LivaNova (LIVN)
www.americanbankingnews.com - December 17 at 11:32 AM
LivaNova (LIVN) Earns "Hold" Rating from Canaccord GenuityLivaNova (LIVN) Earns "Hold" Rating from Canaccord Genuity
www.americanbankingnews.com - December 5 at 8:48 PM
LivaNova (LIVN) PT Raised to $97.00 at Needham & Company LLCLivaNova (LIVN) PT Raised to $97.00 at Needham & Company LLC
www.americanbankingnews.com - December 5 at 9:46 AM
LivaNova PLC (LIVN) Given Average Rating of "Buy" by BrokeragesLivaNova PLC (LIVN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 1 at 6:04 PM
Insider Selling: LivaNova PLC (LIVN) Director Sells 1,830 Shares of StockInsider Selling: LivaNova PLC (LIVN) Director Sells 1,830 Shares of Stock
www.americanbankingnews.com - November 30 at 4:40 PM
LivaNova PLC (LIVN) Director Sells $171,540.00 in StockLivaNova PLC (LIVN) Director Sells $171,540.00 in Stock
www.americanbankingnews.com - November 24 at 10:36 AM
LivaNova Reaches Analyst Target PriceLivaNova Reaches Analyst Target Price
www.nasdaq.com - November 23 at 6:08 AM
LivaNova PLC (LIVN) Price Target Raised to $93.00LivaNova PLC (LIVN) Price Target Raised to $93.00
www.americanbankingnews.com - November 21 at 8:24 AM
BRIEF-LivaNova says breaching co to pay $6 mln if deal with Microport collapsesBRIEF-LivaNova says breaching co to pay $6 mln if deal with Microport collapses
finance.yahoo.com - November 20 at 4:20 PM
LivaNova To Sell CRM Business Franchise For $190 Mln; Updates FY17 OutlookLivaNova To Sell CRM Business Franchise For $190 Mln; Updates FY17 Outlook
www.nasdaq.com - November 20 at 5:17 AM
LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 MillionLivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million
finance.yahoo.com - November 20 at 5:17 AM
BRIEF-Microport Scientifics unit buys CRM business from LivanovaBRIEF-Microport Scientific's unit buys CRM business from Livanova
finance.yahoo.com - November 20 at 5:17 AM
LivaNova PLC (LIVN) Director Sells $81,390.00 in StockLivaNova PLC (LIVN) Director Sells $81,390.00 in Stock
www.americanbankingnews.com - November 16 at 4:50 PM
LivaNova PLCs (LIVN) Hold Rating Reaffirmed at Canaccord GenuityLivaNova PLC's (LIVN) Hold Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - November 14 at 11:03 PM
LivaNova to Present at the Piper Jaffray and Berenberg ConferencesLivaNova to Present at the Piper Jaffray and Berenberg Conferences
finance.yahoo.com - November 8 at 2:01 PM
LivaNova PLC (LIVN) Receives Consensus Recommendation of "Hold" from AnalystsLivaNova PLC (LIVN) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 6 at 8:04 AM
FY2017 Earnings Estimate for LivaNova PLC Issued By Jefferies Group (LIVN)FY2017 Earnings Estimate for LivaNova PLC Issued By Jefferies Group (LIVN)
www.americanbankingnews.com - November 6 at 4:36 AM
LivaNova PLC (LIVN) Given New $89.00 Price Target at Needham & Company LLCLivaNova PLC (LIVN) Given New $89.00 Price Target at Needham & Company LLC
www.americanbankingnews.com - November 5 at 8:56 PM
Jefferies Group LLC Boosts LivaNova PLC (LIVN) Price Target to $91.00Jefferies Group LLC Boosts LivaNova PLC (LIVN) Price Target to $91.00
www.americanbankingnews.com - November 5 at 10:06 AM
LivaNova PLCs (LIVN) "Buy" Rating Reiterated at Piper Jaffray CompaniesLivaNova PLC's (LIVN) "Buy" Rating Reiterated at Piper Jaffray Companies
www.americanbankingnews.com - November 3 at 10:46 PM
Livanova PLC to Host Earnings CallLivanova PLC to Host Earnings Call
finance.yahoo.com - November 3 at 7:52 PM
LivaNova PLC (LIVN) Raised to Buy at ValuEngineLivaNova PLC (LIVN) Raised to Buy at ValuEngine
www.americanbankingnews.com - November 3 at 12:46 AM
LivaNova PLC (LIVN) Issues  Earnings ResultsLivaNova PLC (LIVN) Issues Earnings Results
www.americanbankingnews.com - November 2 at 6:44 PM
Reviewing Nevro Corp. (NVRO) & LivaNova PLC (LIVN)Reviewing Nevro Corp. (NVRO) & LivaNova PLC (LIVN)
www.americanbankingnews.com - November 2 at 3:18 PM
LivaNova PLC (LIVN) Updates FY17 Earnings GuidanceLivaNova PLC (LIVN) Updates FY17 Earnings Guidance
www.americanbankingnews.com - November 2 at 9:52 AM
LivaNova Recognizes Epilepsy Awareness Month This NovemberLivaNova Recognizes Epilepsy Awareness Month This November
finance.yahoo.com - November 2 at 5:36 AM
LivaNova PLC (LIVN) & Its Peers Critical ReviewLivaNova PLC (LIVN) & Its Peers Critical Review
www.americanbankingnews.com - October 31 at 1:06 PM
LivaNova PLC (LIVN) Scheduled to Post Quarterly Earnings on ThursdayLivaNova PLC (LIVN) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - October 26 at 5:00 AM
ETFs with exposure to LivaNova Plc : October 20, 2017ETFs with exposure to LivaNova Plc : October 20, 2017
finance.yahoo.com - October 21 at 6:10 AM
LivaNova PLC (LIVN) vs. Its Rivals Financial ContrastLivaNova PLC (LIVN) vs. Its Rivals Financial Contrast
www.americanbankingnews.com - October 21 at 4:24 AM
LivaNova PLC (LIVN) Given Average Recommendation of "Hold" by BrokeragesLivaNova PLC (LIVN) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 12 at 6:58 AM
ETFs with exposure to LivaNova Plc : October 9, 2017ETFs with exposure to LivaNova Plc : October 9, 2017
finance.yahoo.com - October 9 at 4:29 PM
LivaNova Plc :LIVN-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017LivaNova Plc :LIVN-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 7 at 2:36 AM
Head to Head Analysis: LivaNova PLC (LIVN) versus Its CompetitorsHead to Head Analysis: LivaNova PLC (LIVN) versus Its Competitors
www.americanbankingnews.com - October 4 at 2:36 PM
LivaNova and MicroPort Announce the Approval of Rega Pacemakers by the China Food and Drug AdministrationLivaNova and MicroPort Announce the Approval of Rega Pacemakers by the China Food and Drug Administration
finance.yahoo.com - September 28 at 1:58 AM
LivaNova Announces U.S. Launch of Optiflow Arterial Cannulae FamilyLivaNova Announces U.S. Launch of Optiflow Arterial Cannulae Family
finance.yahoo.com - September 25 at 7:03 PM
Head-To-Head Survey: LivaNova PLC (LIVN) versus CryoLife (CRY)Head-To-Head Survey: LivaNova PLC (LIVN) versus CryoLife (CRY)
www.americanbankingnews.com - September 25 at 2:36 PM
LivaNova PLC (LIVN) Stock Rating Reaffirmed by Canaccord GenuityLivaNova PLC (LIVN) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - September 20 at 9:42 AM
LivaNova PLC (LIVN) Director Daniel Jeffrey Moore Sells 1,000 SharesLivaNova PLC (LIVN) Director Daniel Jeffrey Moore Sells 1,000 Shares
www.americanbankingnews.com - September 19 at 4:28 PM
LivaNova PLC (LIVN) Receives Consensus Rating of "Hold" from AnalystsLivaNova PLC (LIVN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - September 17 at 9:02 AM
LivaNova PLC (LIVN) Lifted to Buy at Needham & Company LLCLivaNova PLC (LIVN) Lifted to Buy at Needham & Company LLC
www.americanbankingnews.com - September 16 at 8:26 PM
LivaNova PLC (LIVN) PT Raised to $80.00LivaNova PLC (LIVN) PT Raised to $80.00
www.americanbankingnews.com - September 15 at 2:34 PM

SEC Filings

LivaNova (NASDAQ:LIVN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

LivaNova (NASDAQ:LIVN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

LivaNova (NASDAQ LIVN) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.